AR112842A1 - Cristal de pirazina - Google Patents

Cristal de pirazina

Info

Publication number
AR112842A1
AR112842A1 ARP180102776A ARP180102776A AR112842A1 AR 112842 A1 AR112842 A1 AR 112842A1 AR P180102776 A ARP180102776 A AR P180102776A AR P180102776 A ARP180102776 A AR P180102776A AR 112842 A1 AR112842 A1 AR 112842A1
Authority
AR
Argentina
Prior art keywords
crystal
pirazine
compound
radiation
ray powder
Prior art date
Application number
ARP180102776A
Other languages
English (en)
Inventor
Toshio Fujiwara
Original Assignee
Nippon Shinyaku Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nippon Shinyaku Co Ltd filed Critical Nippon Shinyaku Co Ltd
Publication of AR112842A1 publication Critical patent/AR112842A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D241/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Analysing Materials By The Use Of Radiation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Cephalosporin Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

Un cristal de 2-{4-[N-(5,6-difenilpirazin-2-il)-N-isopropilamino]butiloxi}acetato (compuesto B). Un cristal de la forma I de compuesto B, que muestra picos en ángulos de difracción (2q) de 6,4º, 8,1º, 9,5º, 10,9º, 13,2º, 15,7º, 17.0º, 19,5º, 20,3º, 21,0º y 22,8º en un espectro de difracción de polvos por rayos X obtenido usando una radiación Cu-Ka (l = 1,54 Å). Un cristal de la forma II de compuesto B, que muestra picos en ángulos de difracción (2q) de 9,6º, 11,4º, 11,7º, 16,3º, 17,5º, 18,5º, 18,7º,19,9º, 20,1º, 21,0º y 24,6º en un espectro de difracción de polvos por rayos X obtenido usando una radiación Cu-Ka (l = 1,54 Å).
ARP180102776A 2017-09-28 2018-09-27 Cristal de pirazina AR112842A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2017187296 2017-09-28

Publications (1)

Publication Number Publication Date
AR112842A1 true AR112842A1 (es) 2019-12-18

Family

ID=65902864

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP180102776A AR112842A1 (es) 2017-09-28 2018-09-27 Cristal de pirazina

Country Status (18)

Country Link
US (3) US10906879B2 (es)
EP (2) EP4371617A2 (es)
JP (3) JP7160043B2 (es)
KR (2) KR102675320B1 (es)
CN (2) CN117510418A (es)
AR (1) AR112842A1 (es)
AU (2) AU2018338856B2 (es)
BR (1) BR112020005428A2 (es)
CA (1) CA3076877A1 (es)
CO (1) CO2020003424A2 (es)
IL (1) IL273430A (es)
MX (2) MX2020007315A (es)
PH (1) PH12020550149A1 (es)
RU (1) RU2020112117A (es)
SG (1) SG11202002443QA (es)
TW (2) TWI834536B (es)
UA (1) UA126928C2 (es)
WO (1) WO2019065792A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4371617A2 (en) * 2017-09-28 2024-05-22 Nippon Shinyaku Co., Ltd. Crystal
WO2021023271A1 (zh) * 2019-08-06 2021-02-11 南京明德新药研发有限公司 作为前列环素受体激动剂的化合物的晶型及其制备方法
TW202114998A (zh) * 2019-08-19 2021-04-16 日商日本新藥股份有限公司 鹽

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI316055B (es) * 2001-04-26 2009-10-21 Nippon Shinyaku Co Ltd
BRPI0908491A2 (pt) 2008-02-28 2015-08-11 Nippon Shinyaku Co Ltd Inibidor de fibrose
WO2009154246A1 (ja) 2008-06-19 2009-12-23 日本新薬株式会社 勃起不全治療剤
WO2009157397A1 (ja) 2008-06-23 2009-12-30 日本新薬株式会社 非ステロイド性抗炎症剤投与に伴う腸管傷害治療剤
SI2289518T1 (sl) 2008-06-23 2017-02-28 Nippon Shinyaku Co., Ltd. Terapevtsko sredstvo za vnetno črevesno bolezen
WO2009157396A1 (ja) 2008-06-23 2009-12-30 日本新薬株式会社 脊柱管狭窄症治療剤
KR101587071B1 (ko) 2008-07-23 2016-01-20 도레이 카부시키가이샤 만성 신부전 처치제
US8791122B2 (en) 2009-06-26 2014-07-29 Nippon Shinyaku Co., Ltd. Form-I crystal of 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulfonyl)acetamide and method for producing the same
CN106279047B (zh) * 2015-05-13 2019-05-03 普济生物科技（台州）有限公司 一种前列环素受体激动剂的制备方法
WO2017042828A2 (en) * 2015-09-10 2017-03-16 Megafine Pharma (P) Ltd. Process for the preparation of selexipag and intermediates thereof
WO2017060827A1 (en) 2015-10-07 2017-04-13 Lupin Limited An imrpoved process for the preparation of selexipag or its pharmaceutically acceptable salts
EP3481807A4 (en) * 2016-07-05 2020-01-15 Maithri Drugs Private Limited NEW PROCESS FOR THE PREPARATION OF 2- {4 - [(5,6-DIPHENYL PYRAZIN-2-YL) (ISOPROPYL) AMINO] BUTOXY} -N- (METHYLSULFONYL) ACETAMIDE AND NEW POLYMORPHS THEREOF
CN106957269A (zh) 2016-12-21 2017-07-18 南京艾德凯腾生物医药有限责任公司 一种成人肺动脉高压治疗药物赛乐西帕的制备方法
CN107365275B (zh) * 2017-06-14 2020-07-03 杭州华东医药集团新药研究院有限公司 高纯度的赛乐西帕
EP4371617A2 (en) * 2017-09-28 2024-05-22 Nippon Shinyaku Co., Ltd. Crystal

Also Published As

Publication number Publication date
CO2020003424A2 (es) 2020-06-19
US20200223804A1 (en) 2020-07-16
TW201920121A (zh) 2019-06-01
CN117510418A (zh) 2024-02-06
TWI801421B (zh) 2023-05-11
AU2018338856A1 (en) 2020-04-16
SG11202002443QA (en) 2020-04-29
KR102675320B1 (ko) 2024-06-14
TWI834536B (zh) 2024-03-01
CN111263754A (zh) 2020-06-09
AU2018338856B2 (en) 2023-09-21
UA126928C2 (uk) 2023-02-22
WO2019065792A1 (ja) 2019-04-04
JP7160043B2 (ja) 2022-10-25
PH12020550149A1 (en) 2021-02-08
KR20240042215A (ko) 2024-04-01
JPWO2019065792A1 (ja) 2020-10-22
CA3076877A1 (en) 2019-04-04
AU2023274142A1 (en) 2023-12-21
MX2023004668A (es) 2023-05-19
US20210114995A1 (en) 2021-04-22
TW202332673A (zh) 2023-08-16
JP7485738B2 (ja) 2024-05-16
IL273430A (en) 2020-05-31
RU2020112117A (ru) 2021-10-28
EP4371617A2 (en) 2024-05-22
US11655218B2 (en) 2023-05-23
JP2022173401A (ja) 2022-11-18
EP3689854A1 (en) 2020-08-05
EP3689854A4 (en) 2021-06-09
US20230303500A1 (en) 2023-09-28
MX2020007315A (es) 2020-08-20
BR112020005428A2 (pt) 2020-09-29
KR20200060393A (ko) 2020-05-29
US10906879B2 (en) 2021-02-02
JP2024045685A (ja) 2024-04-02

Similar Documents

Publication Publication Date Title
AR122395A2 (es) Formas cristalinas de 5-cloro-n2-(2-isopropoxi-5-metil-4-piperidin-4-il-fenil)-n4-[2-(propan-2-sulfonil)-fenil]-pirimidin-2,4-diamina
PH12018501180A1 (en) 2-(3-ethanesulfonyl pyridine-2-yl)-5-(trifluoromethanesulfonyl) benzoxazole crystal
AR112842A1 (es) Cristal de pirazina
PH12016501813A1 (en) 1,3-benzodioxole derivative
CL2016000117A1 (es) Autotaxina inhibidores comprende un anillo heteroaromático-bencilamina ciclo basico
ECSP12011799A (es) Compuestos de espiropiperidina y uso farmacéutico de los mismos
TR201903892T4 (tr) Diyabet ve obezitenin tedavisinde kullanılan dihidrobenzofuran bileşikleri.
AR096758A1 (es) Inhibidores cristalinos de bromodominios
PH12015501993B1 (en) Pyrazole-amide compound and medicinal uses therefor
PH12015501813A1 (en) Monocyclic pyridine derivative
MX2018009459A (es) Derivado de sulfonamida y composicion farmaceutica que contiene el mismo.
CA2914620C (en) Heterocyclic derivatives and use thereof
PH12016500480A1 (en) Antibacterial 2h-indazole derivatives
AR103444A1 (es) Forma cristalina de un derivado de bencimidazol y un método de preparación de los mismos
AR095435A1 (es) Formas salinas del (2-(2-(4-fluorofenil)tiazol-4-il)propan-2-il)carbamato de (s)-quinuclidin-3-ilo
AR107963A1 (es) Forma cristalina de sales de 1-(5-(2,4-difluorfenil) -1-((3-fluorfenil)sulfonil)-4-metoxi-1h-pirrol-3-il)-n-metilmetanamina
NI201800065A (es) Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento de cáncer
BR112017016396A2 (pt) composto, composição farmacêutica, uso de um composto, e, método.
EP4335500A3 (en) Methods for the synthesis of deuterated dextromethorphan
WO2015017378A3 (en) Novel copper-cysteamine and methods of use
AR106849A1 (es) Compuestos de bis-piridazina y su uso en el tratamiento del cáncer
AR107441A1 (es) Forma cristalina de cobicistat
ES2489467T3 (es) Polimorfo novedoso del clorhidrato del éster (6-dimetilaminometil-2-naftalenílico) del ácido (4-hidroxicarbamoilfenil)-carbámico
MX2017003607A (es) Sales de clorhidrato de aluminio que exhiben un pico 1 sec alto.
AU2018264313A1 (en) Indolizine derivatives and application thereof in medicine